No. 1: Radient Pharmaceuticals (RXPC)
The winner by a mile. When I compiled this list of drug-stock losers, I excluded pink-sheet and bulletin-board issues, but Radient was granted an exemption since the stock sank to the OTC in June.In 2011, who could forget Radient's business deals with a dead Indian prime minister or pseudo-partnership with the Mayo Clinic? Then there was Radient's massive loan default, the reluctant disclosure that its India joint venture was a bust and the delisting from Amex. The stock: It's not possible to lose more than 100% but Radient came close with the shares plunging 99.6% in 2011. >>To see these stocks in action, visit the 5 Biggest Drug-Stock Losers of 2011 portfolio on Stockpickr. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.